MedTrace Logo

Use of r-hLH (Luveris) in Donors Previously Treated With r-hFSH (Gonal F)

NCT01223079 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-03-05

No results posted yet for this study

Summary

The purpose of the study is to compare the safety and efficacy of r-hLH to r-hFSH in the late follicular phase of young women undergoing controlled ovarian stimulation for oocyte donation.

Conditions

  • Outcome During r-hFSH Stimulation
  • Outcome During r-hFSH and r-hLH Stimulation

Interventions

DRUG

r-hFSH

r-hFSH dose to be determined by the patient's primary doctor and adjusted according to their response

DRUG

r-hFSH and r-hLH

Patients will begin r-hLH at 300IU/day when there are 2 follicles greater than or equal to 14mm.

Sponsors & Collaborators

  • Reproductive Medicine Associates of New Jersey

    lead OTHER

Principal Investigators

  • Richard T Scott, MD · Reproductive Medicine Associates of New Jersey

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
32 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2007-12-31
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01223079 on ClinicalTrials.gov